Retatrutide and Fatty Liver Disease: What the MASLD Trial Data Shows
A phase 2 substudy found retatrutide cut liver fat by more than 80% in people with obesity and fatty liver. What the MASLD data shows and what it cannot yet tell us.

Important: investigational medicine notice. Retatrutide has not received marketing authorisation from the MHRA and cannot be legally prescribed, dispensed or sold in the UK outside of an authorised clinical trial. This article is for information only. It is not medical advice and is not a recommendation to seek or use retatrutide. If you are considering weight-management medication, speak to your GP or a regulated UK prescriber about MHRA-approved options.
Retatrutide and Fatty Liver Disease: What the MASLD Trial Data Shows
Fatty liver disease is one of the most common long-term complications of obesity, and one of the conditions retatrutide is being studied for. The main evidence so far is a phase 2 substudy, published in Nature Medicine in 2024, that measured liver fat directly by MRI. This article explains what that study found, why the glucagon part of retatrutide may matter for the liver, and what has not yet been shown.
What the evidence supports is that retatrutide reduced liver fat substantially over 24 to 48 weeks in a small group of people with obesity and fatty liver. It does not yet show that retatrutide reverses liver inflammation or scarring, which are the outcomes that determine long-term liver health.
The short answer
In a substudy of 98 adults with obesity and at least 10% liver fat, retatrutide 12 mg reduced liver fat by an average of about 82% at 24 weeks. By 48 weeks, most people on the higher doses had liver fat in the normal range. The study did not assess inflammation or fibrosis, and retatrutide is not licensed.
What MASLD is
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the current name for what used to be called non-alcoholic fatty liver disease (NAFLD). It means excess fat in the liver linked to factors such as obesity, type 2 diabetes or high blood pressure. In some people it progresses to MASH, where fat is accompanied by inflammation and liver cell damage, and then to fibrosis (scarring) and cirrhosis.
Liver fat itself is not the main danger. Fibrosis is the strongest predictor of serious liver problems, which is why trials aiming for a licence in this area are judged on inflammation and scarring, usually assessed by liver biopsy.
Why retatrutide might affect liver fat
Retatrutide acts on three hormone receptors: GLP-1, GIP and glucagon. Weight loss alone reduces liver fat. Glucagon receptor activity is also thought to increase fat breakdown and energy use in the liver directly, which may add to the effect. This is a proposed mechanism, supported by early data rather than proven in people. Our article on how retatrutide works covers the three receptors in more detail.
What the Nature Medicine substudy found
The substudy, led by Arun Sanyal, drew on participants from the phase 2 obesity trial. It included 98 adults with obesity and liver fat of 10% or more, measured by MRI proton density fat fraction (MRI-PDFF), a scan that estimates the percentage of liver tissue made up of fat. Participants received retatrutide 1 mg, 4 mg, 8 mg or 12 mg, or placebo.
The study reported:
- At 24 weeks: average relative reductions in liver fat of more than 80% at the 8 mg and 12 mg doses, around 82% at 12 mg, with almost no change on placebo.
- At 48 weeks: liver fat below 5%, the threshold usually considered normal, in 89% of people on 8 mg and 93% on 12 mg.
- Link with weight: reductions in liver fat tracked closely with weight loss and with improvements in insulin sensitivity.
What the evidence does not show
- Inflammation and fibrosis. The substudy measured fat, not the inflammation and scarring that drive outcomes. No liver biopsies were used to assess these.
- Sample size. Fewer than 100 people took part, split across five groups.
- Duration. Forty-eight weeks says nothing about long-term liver outcomes such as cirrhosis.
- People with advanced disease. Participants had fatty liver, not established MASH with significant fibrosis.
- Phase 3 confirmation. Dedicated phase 3 liver trials have not yet reported.
What this means in the UK
As of October 2026, retatrutide has no MHRA marketing authorisation and cannot be prescribed for fatty liver or any other condition outside a clinical trial. In NHS care, weight loss through diet and activity remains central to managing MASLD, and people with abnormal liver tests or suspected fatty liver are assessed by their GP, with referral to a liver specialist where fibrosis is suspected. Licensed weight-management medicines are covered in our weight loss medication UK pillar guide.
Symptoms such as yellowing of the skin or eyes, dark urine, swelling of the abdomen or persistent pain under the right ribs need prompt medical assessment.
The bottom line
Retatrutide produced some of the largest reductions in liver fat reported for any weight-loss medicine, with most people on higher doses reaching normal liver fat levels within 48 weeks. The study was small, short and measured fat rather than the scarring that determines long-term risk, so the effect on liver disease itself is not yet known. Anyone concerned about fatty liver should speak to their GP or a regulated UK prescriber.
Sources and further reading
- Sanyal AJ, Kaplan LM, Frías JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30:2037–2048.
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514–526.
- NHS: Non-alcoholic fatty liver disease (NAFLD)
- ClinicalTrials.gov: A Study of LY3437943 in Participants Who Have Obesity or Overweight, NCT04881706
Related reading from the Health Hub
- What is retatrutide? A clinical overview
- Retatrutide side effects and safety profile
- Nutrition for sustainable weight loss: UK pillar guide
Always speak to your GP or a regulated UK prescriber before starting, stopping or changing any medication. This article is for general information only and does not replace individual medical advice.
Get weekly weight loss tips
Join our newsletter for provider updates, expert guidance, and exclusive offers — no spam.
Subscribe free